Resilient Amgen stock trades near a one-year high as Q2 2026 earnings and guidance impress
Published on 08/28/2026 at 06:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen Inc. (US0311621009) stock is holding at an elevated level in late August 2026, with shares opening at $440.34 as of August 27, 2026, very close to the company’s one-year high of $447.03 and well above the consensus target price that many investors track.
The latest move comes in the wake of Amgen’s second-quarter 2026 results, where the company reported revenue of $10.05 billion and adjusted earnings of $6.29 per share, both ahead of market expectations and supported by broad-based growth across its portfolio.
For investors, the combination of a strong Q2 earnings beat, raised full-year guidance and a share price near its recent high underlines how much confidence the market currently assigns to Amgen’s execution.
Q2 2026 earnings beat and guidance raise
Amgen’s most recent quarterly report for Q2 2026 showed revenue of $10.05 billion, an increase of 9.5 percent compared with the same quarter a year earlier, highlighting solid top-line momentum heading into the second half of 2026. A detailed earnings overview notes that the business had revenue of $10.05 billion versus analyst estimates of $9.43 billion, underscoring a clear beat on expectations.
On the bottom line, Amgen delivered adjusted earnings of $6.29 per share in Q2 2026, exceeding the consensus forecast of $5.62 by $0.67 per share and improving from $6.02 per share in the prior-year quarter. The same earnings summary highlights that Amgen’s revenue beat of 9.5 percent year over year came alongside strong profitability, with a net margin of 22.95 percent and return on equity of 124.14 percent for the quarter.
Importantly for 2026, Amgen has raised its full-year outlook on the back of these Q2 numbers. Guidance for fiscal 2026 now calls for adjusted earnings of $22.30 to $23.50 per share, up from the previous range and supported by portfolio-wide execution; research analysts currently forecast that Amgen will deliver around $22.92 in earnings per share for the year, placing the consensus close to the midpoint of management’s new range. Guidance commentary indicates that the earnings outlook has been formally set at $22.300 to $23.500 EPS for FY 2026, with analysts’ expectations adjusting higher in response.
Revenue growth and margin performance together provide a clear quantified comparison: relative to the same quarter in 2025, Q2 2026 revenue increased from a lower base by 9.5 percent to $10.05 billion, while EPS improved from $6.02 to $6.29 per share, showing that Amgen is not only growing but doing so with strong profitability. For long-term shareholders, this type of simultaneous revenue and earnings expansion tends to be a favorable signal for valuation resilience.
Dividend, valuation context and share-price levels
Beyond earnings, Amgen continues to return cash to shareholders. The company recently declared a quarterly dividend of $2.52 per share, which on an annualized basis amounts to $10.08 per share and equates to a dividend yield of 2.3 percent at prevailing prices. Dividend details specify that investors of record on August 21, 2026, will receive the $2.52 payment on September 11, 2026, providing a tangible income stream that reinforces Amgen’s appeal for income-oriented portfolios.
From a market perspective, Amgen shares have been trading firmly. Several recent portfolio filings and performance rundowns show NASDAQ:AMGN opening at $440.34 on August 27, 2026, very close to the stock’s 52-week high of $447.03 and well above a 200-day moving average quoted at $363.86. A recent price-performance article describes how Amgen opened at $440.34 while closing in on its one-year high of $447.03, highlighting a premium relative to its longer-term trend.
At the same time, market data summaries point out that Wall Street’s consensus rating on Amgen presently sits at Hold, with an average price target of $380.43, which is meaningfully below the current share price around the low $440s. Consensus figures reveal that the average target of $380.43 places the stock more than 15 percent under the current market level of $440.34, suggesting that the market is pricing in upside beyond the typical analyst view, or that targets may need to catch up with the latest guidance and product momentum.
For investors evaluating entry points, one concrete comparison stands out: with the share price at $440.34 and the average price target at $380.43, Amgen is trading roughly $59.91 above consensus, a premium that reflects confidence but also raises the bar for future execution. The one-year high of $447.03 is only $6.69 away from the latest opening level, meaning the shares are effectively within a narrow band of their recent peak. This proximity to a 52-week high often prompts investors to consider both growth prospects and valuation discipline in tandem.
Pipeline momentum highlighted by Tezspire results
Earnings and guidance are only part of the story for Amgen in late August 2026. The company’s pipeline is also delivering new data, which is important for sustaining long-term growth beyond current products. On August 27, 2026, Amgen announced that TEZSPIRE (tezepelumab) demonstrated positive Phase 3 results in eosinophilic esophagitis, achieving both co-primary and all key secondary endpoints in the study. The official press release outlines that TEZSPIRE met its efficacy objectives in eosinophilic esophagitis, adding another potential indication to its profile as a biologic therapy targeting inflammatory pathways.
While the press release focuses on clinical end points rather than financial figures, the development has clear strategic implications. Eosinophilic esophagitis is a chronic, immune-mediated disease of the esophagus, and effective treatments can address unmet medical needs for patients with symptoms such as dysphagia and food impaction. For Amgen, successfully expanding TEZSPIRE’s label into additional indications can help drive incremental revenue over time, complementing existing usage in severe asthma and supporting the company’s broader inflammation portfolio.
From an investor angle, positive late-stage data like this tends to reinforce confidence that Amgen’s pipeline can sustain growth beyond current blockbusters. When combined with the Q2 2026 revenue increase of 9.5 percent and a raised EPS guidance range of $22.30 to $23.50 for the year, pipeline progress bolsters the argument that the current premium valuation is underpinned by both near-term financial performance and longer-term innovation potential.
Representative product: TEZSPIRE in severe asthma
Among Amgen’s marketed medicines, TEZSPIRE has emerged as a representative product that illustrates the company’s strategy in immunology and respiratory disease. Originally approved for severe asthma, TEZSPIRE is a human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that plays a central role in the inflammatory cascade across multiple type 2 inflammatory pathways.
For patients with severe, uncontrolled asthma, TEZSPIRE is administered as a subcutaneous injection and is indicated as an add-on maintenance therapy to help reduce exacerbations and improve lung function. By acting upstream in the inflammatory pathway, it can potentially benefit a broad range of patients irrespective of specific biomarker thresholds, which differentiates it from some other biologic treatments that require elevated eosinophil counts or other marker-defined criteria.
From a commercial standpoint, TEZSPIRE fits neatly into Amgen’s strategy of building durable franchises in inflammatory and specialty conditions. The newly reported positive Phase 3 results in eosinophilic esophagitis suggest that the medicine’s reach could expand further if regulators ultimately approve additional indications, potentially adding another source of revenue growth on top of its existing asthma business. For investors, following TEZSPIRE’s trajectory offers insight into how Amgen can leverage a single biologic asset across multiple indications to drive high-margin sales.
Stock level and investor takeaway
As of August 27, 2026, Amgen stock on the NASDAQ exchange opened at $440.34 in USD, trading just below its one-year high of $447.03 and comfortably above a 200-day moving average stated at $363.86. This positioning underscores that the market is valuing Amgen as a resilient large-cap biotech with strong current earnings, a raised guidance range of $22.30 to $23.50 in EPS for fiscal 2026, and an annualized dividend of $10.08 per share yielding 2.3 percent at prevailing prices.
For investors, the key numbers now are the quantified gap between the share price and the $380.43 consensus target, the high-single-digit 9.5 percent revenue growth achieved in Q2 2026, and the EPS beat of $0.67 versus expectations to reach $6.29 per share in the quarter. How Amgen continues to execute on its diversified product portfolio, including launches and label expansions for assets such as TEZSPIRE, will determine whether the current premium valuation near the one-year high remains justified over the coming quarters.
Fact box
Company: Amgen Inc.
ISIN: US0311621009
Ticker: AMGN
Exchange: Nasdaq (US)
Price (as of August 27, 2026, 4:00 p.m. ET): $440.34 USD
Market cap: data referenced in market overviews, with shares trading close to a one-year high of $447.03 as of late August 2026
Sector / Industry: Biotechnology
Index membership: S&P 500
